Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 198
Titolo Data di pubblicazione Autore(i) File
Complete reversion of imatinib-induced hepatotoxicity in chronic myeloid leucemia patients by low-intermediate dose corticosteroid. 2005 D. Ferrero; EM. Pogliani; G. Rege Cambrin; C. Fava; G. Mattioli; C. Dellacasa; V. Giai; M. Genuardi; P. Perfetti; M. Fumagalli; M. Boccadoro
FISH-MLL abnormalities in patients in Acute Myeliodblastic Leukemia and association with FLT3 and MLL internal duplication. 2006 Giugliano E; Rege-Cambrin G; Scaravaglio P; Diverio D; Serra A; Mancini M; Brunetto V; Ferranti G; Mattioli G; Fava C; Fimognari M; Ulisciani S; Pane F; Lo Coco F; Saglio G.
Prolonged molecular remission in a late chronic phase CML patient after discontinuation of Imatinib Treatment. 2006 Rege-Cambrin G; Fava C; Mattioli G; Giugliano E; Gottardi E; Fava M; Ulisciani S; Scaravaglio P; Saglio G.
Monitoring cytogenetic and molecular response in chronic myeloid leucemia after imatinib mesylate treatment. 2006 Rege Cambrin G; Giuliano E; Gottardi E.; Fava M.; Fava C.; Mattioli G.; Ulisciani S.; Brunetto V.; Schippa M.;Liberati M.;Saglio G.
Mitoxantrone-related acute myeloid leukaemia, induced one year after the discontinuation of mitoxantrone therapy 2006 Capobianco, M; Malucchi, S; Bosa, M; Fava, C; Avonto, L; Bertolotto, A
A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML. 2006 Emilia Giugliano; Dario Ferrero; Carmen Fava; Chiara Dellacasa; Giovanna Mattioli; Patrizia Scaravaglio; Enrico Gottardi; Stefano Ulisciani; Filomena Daraio; Giuseppe Saglio; Giovanna Rege.
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 2006 FERRERO D; POGLIANI EM; REGE-CAMBRIN G; FAVA C; MATTIOLI G; DELLACASA C; CAMPA E; PERFETTI P; FUMAGALLI M; BOCCADORO M
Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI). 2007 Carmen Fava; Hagop M. Kantarjian; Elias Jabbour; Mary Beth Rios; Guillermo Garcia-Manero; Susan O’Brien; and Jorge Cortes.
Kinetics of Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients May Predict Persistent Polymerase Chain Reaction Negativity after Imatinib Discontinuation. 2007 Giovanna Rege-Cambrin; Stefano Ulisciani; Giovanna Mattioli; Carmen Fava; Emilia Giugliano; Vanessa Brunetto; Enrico Gottardi; Milena Fava; and Giuseppe Saglio.
Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib. 2007 Nitin Jain; Hagop M. Kantarjian; Carmen Fava; Deborah Thomas; Jan A. Burger; Gautam Borthakur; Odeal Pate; and Jorge Cortes.
Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). 2007 Bruno Martino; Giovanna Rege Cambrin; Antonella Gozzini; Fabio Stagno; Massimo Breccia; Giorgina Specchia; Ester Orlandi; Ester Pungolino; Franca Falzetti; Sara Galimberti; Carmen Fava; Antonio Marino; and Francesco Nobile.
Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML) 2008 Santos FPS ; Kantarjian H; Fava C; O’Brien S; Garcia-Manero G; Kornblau S; Ravandi F; Wierda W; Cortes J
Outcome of First Salvage Therapy in Core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal 2008 Fava C; Blamble D; O’Brien S; Garcia-Manero G; Pierce S; Kantarjian H; Borthakur G
Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis 2008 Capobianco M; Malucchi S; Ulisciani S; Fava C; Cambrin GR; Avonto L; Saglio G; Bertolotto A
Development and targeted use of nilotinib in chronic myeloid leukemia. 2008 Fava C; Kantarjian H; Cortes J; Jabbour E
Clinical Use of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia (CML) 2008 Ault P; Kantarjian HM; Bryan J; Prescot H; Alvarado Y; Fava C; Cortes J
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. 2008 Fava C; Cortes J
Occourrence of pleural effusions during dasatinib treatment in elderly chronic myelogenous leukemia patients. 2009 Latagliata R.; Breccia M.; Stagno F.; Luciano L.; Gozzini A.; Annunziata M.; De Matteis S.; Albano F.; Ulisciani S.; Pregno P.; Pacilli M.; Abruzzese E.; Martino B.; Tiribelli M.; Avanzini P.; Pacilli L.; Vigneri P.; Fabbricini R; Russo Rossi A.; Sica S.; Vitolo U.; Montefusco E.; Fava C.; Ferrara F.; Santini V.; Pane F.; Di Raimondo F.; Alimena G.
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. 2009 Fava C; Kantarjian HM; Jabbour E; O'Brien S; Jain N; Rios MB; Garcia-Manero G; Ravandi F; Verstovsek S; Borthakur G; Shan J; Cortes J
Standard management of patients with chronic myeloid leukemia. 2009 Fava C; Cortés JE; Kantarjian H; Jabbour E
Mostrati risultati da 1 a 20 di 198
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile